Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

C. Grohe,R. S. Herbst,M. Tsuboi,T. John,M. Majem,J. W. Goldman,S. -W. Kim, D. Marmol,Y. Rukazenkov,Y. -L. Wu, W. Engel-Riedel

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 62|浏览6

暂无评分

摘要

LBA5Background: Osimertinib is a 3rd-generation, CNS-active, EGFR-TKI with superior efficacy to comparator EGFR-TKI (gefitinib/erlotinib) in treatment-naive EGFRm advanced NSCLC. Approx. 30% of pts...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要